BioNTech’s oncology vaccine trial sees all patients living kidney cancer-free
Vaccines generated using the cells left over after tumour removal surgery could help to keep patients from redeveloping ...
Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.
Shares of companies developing psychedelic treatments jumped while those of vaccine makers slipped after a Senate committee advanced the nomination of Robert F. Kennedy Jr. to lead the Health and ...
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
Shares of vaccine companies fell on Tuesday after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead ...
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of ...
Investing2d
Moderna and BioNTech shares fall after Senate committee vote RFK Jr.
Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...
RFK Jr. HHS nomination advances out of Senate Finance Committee
The Senate Finance Committee advances the nomination of Robert F. Kennedy Jr. for HHS Secretary amid a party-line vote. Read ...
BioNTech price target lowered to $147 from $150 at BofA
BofA lowered the firm’s price target on BioNTech (BNTX) to $147 from $150 and keeps a Buy rating on the shares. On the Q4 call, the firm will ...
BioNTech fair value analysis yields 51% return in six months
Investing.com's Fair Value model demonstrated its effectiveness once again, identifying a significant opportunity in BioNTech SE (NASDAQ:BNTX) that resulted in a remarkable 51% return over just six ...
InvestorsHub on MSN2d
Moderna, BioNTech Shares Down After Senate Committee Vote To RFK Jr.’s Nomination
The U.S. Senate Finance Committee has voted to advance Robert F. Kennedy Jr.’s nomination for Secretary of Health and Human ...
BioNTech Completes Acquisition of Biotheus
Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...